CNS Pharmaceuticals Inc
NASDAQ:CNSP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Midwest Energy Emissions Corp
OTC:MEEC
|
US |
|
U
|
USD Partners LP
OTC:USDP
|
US |
CNS Pharmaceuticals Inc
Total Assets
CNS Pharmaceuticals Inc
Total Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
CNS Pharmaceuticals Inc
NASDAQ:CNSP
|
Total Assets
$8.6m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Assets
$199.2B
|
CAGR 3-Years
1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Assets
$90B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Total Assets
$208.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
6%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Total Assets
$136.9B
|
CAGR 3-Years
8%
|
CAGR 5-Years
8%
|
CAGR 10-Years
3%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Assets
$112.5B
|
CAGR 3-Years
31%
|
CAGR 5-Years
19%
|
CAGR 10-Years
12%
|
|
CNS Pharmaceuticals Inc
Glance View
CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. The company is headquartered in Houston, Texas and currently employs 3 full-time employees. The company went IPO on 2019-11-08. The firm is focused on development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The firm is developing its lead drug candidate, Berubicin for the treatment of glioblastoma. Glioblastoma are tumors that arise from astrocytes, which are star-shaped cells making up the supportive tissue of the brain. Berubicin is an anthracycline, a class of drugs that are among the chemotherapy drugs, which intercalates into Deoxyribonucleic acid (DNA) and interrupts topoisomerase II activity, resulting in the inhibition of DNA replication and repair, and RNA and protein synthesis. The firm is advancing the development of its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents.
See Also
What is CNS Pharmaceuticals Inc's Total Assets?
Total Assets
8.6m
USD
Based on the financial report for Dec 31, 2025, CNS Pharmaceuticals Inc's Total Assets amounts to 8.6m USD.
What is CNS Pharmaceuticals Inc's Total Assets growth rate?
Total Assets CAGR 5Y
-11%
Over the last year, the Total Assets growth was -1%. The average annual Total Assets growth rates for CNS Pharmaceuticals Inc have been -13% over the past three years , -11% over the past five years .
